Baiyunshan Pharma proceeding with capital increase in biopharmaceuticals

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. (SSE:600332) announced that it is proceeding with its plan to increase capital in its subsidiary, Baiyunshan Biopharmaceuticals. On June 30, 2025, the company, along with several investment funds and Baiyunshan Biopharmaceuticals, entered into a capital increase agreement, effective the same day. The key terms of the capital increase remain unchanged. Following the capital increase, Baiyunshan Pharma's direct and indirect equity stake in Baiyunshan Biopharmaceuticals will remain at 50.00%. Baiyunshan Biopharmaceuticals will remain a subsidiary of Guangzhou Baiyunshan Pharmaceutical Holdings, and its financial performance will continue to be consolidated into the company's financial statements.